Novavax Aims for Billions Covid Vaccine Doses Could Be Available by End of 2021

Some of the world’s largest biopharma companies are working to deliver safe and effective COVID-19 vaccines, but at the same time, a much smaller biotech has laid out its own big ambitions in the field. Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives say. On a conference call Monday, chief medical officer Filip Dubovsky said the Gaithersburg, MD-based biotech expects to be able to make "well over a couple billion units" each year, starting in 2021. That would easily outpace U.S. demand, which Dubovsky estimated will come in at 500 million to 600 million doses annually.

Spotlight

Spotlight

Related News